Roche Doubles Down on Potential Alzheimer’s Drug as Competitors’ Drugs Fail

In a field with multi-billion dollar potential, Roche is more than doubling the size of its Phase II/III clinical trial for what it considers the most advanced monoclonal antibody (mAb) in development to treat early Alzheimer’s disease (AD). But the consensus among analysts is that chances are slim for mAbs that target beta amyloids, Bernstein’s Timothy Anderson said. And gantenerumab is similar to Pfizer, Johnson & Johnson and Elan’s failed bapineuzumab in the way it works, Anderson added.
Drug Industry Daily